0.8 ML Fondaparinux sodium 12.5 MG/ML Prefilled Syringe

Known as: FONDAPARINUX SODIUM 10 mg in 0.8 mL SUBCUTANEOUS INJECTION, SOLUTION [Fondaparinux Sodium], FONDAPARINUX NA 10MG/0.8ML INJ,SYRINGE,0.8ML [VA Product], FONDAPARINUX 10MG/0.8ML INJ SYR 0.8ML 
 
National Institutes of Health

Topic mentions per year

Topic mentions per year

2010-2017
01220102017

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2018
2018
AIMS Increased exposure to fondaparinux, as observed in patients with renal impairment, may increase bleeding risk. This study… (More)
Is this relevant?
2017
2017
Heparan sulfate is identified as a ligand receptor for polynuclear platinum anti-cancer agents through sulfate cluster binding… (More)
Is this relevant?
2013
2013
BACKGROUND Anti-PF4/heparin antibodies are frequently generated after coronary artery bypass grafting (CABG) surgery, with… (More)
Is this relevant?
2012
2012
BACKGROUND Thromboprophylaxis with rivaroxaban (R) is superior to enoxaparin in patients undergoing major orthopedic surgery (MOS… (More)
Is this relevant?
2012
2012
Fondaparinux, a selective activator factor X (factor Xa) inhibitor, is effective and safe for preventing venous thromboembolism… (More)
  • table 1
  • figure 1
  • table 2
  • figure 2
  • figure 3
Is this relevant?